Potassium magnesium supplementation for four weeks improves small distal artery compliance and reduces blood pressure in patients with essential hypertension

Geru Wu, Hongyan Tian, Ke Han, Yutao Xi, Yan Yao, Aiqun Ma

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

It has been postulated that the loss of arterial compliance may precede cardiovascular diseases, and that arterial compliance is an important parameter to consider when evaluating arterial diseases such as essential hypertension (EH) and the effects of antihypertensive treatment. In all, 133 EH patients and 147 healthy subjects were enrolled in this study. Large arterial compliance (C1) and small arterial compliance (C2) were measured by the CVProfilor™ DO-2020 CardioVascular Profiling System. Thirty-five patients randomly received magnesium potassium supplementation (magnesium, 70.8 mg/d; potassium, 217.2 mg/d) for four weeks, and 32 patients received lacidipin (4mg/d) as a control. Before and after the four weeks, blood pressure, C1, and C2 were measured. It was found that arterial compliance was significantly lower in EH patients compared with healthy subjects (C1: 12.53 ± 0.33 vs. 15.63 ± 0.30 ml/mmHg × 10, p + and Mg 2+ supplementation, systolic and diastolic BP decreased 7.83 ± 1.87 mm Hg and 3.67 ± 1.03 mm Hg, and C1 and C2 compliance values increased 12.44% ± 4.43% and 45.25% ± 6.67%, respectively. Decreases in systemic vascular resistance (mean arterial pressure divided by cardiac output) by 11.9% and 16.6 % (p < 0.01) were seen between the drug-induced changes, respectively. Both large arterial compliance and small arterial compliance were decreased in essential hypertension patients. In essential hypertension patients, magnesium and potassium supplementation could improve small arterial compliance, while lacidipine improved large arterial compliance significantly.

Original languageEnglish (US)
Pages (from-to)489-497
Number of pages9
JournalClinical and Experimental Hypertension
Volume28
Issue number5
DOIs
StatePublished - Jun 1 2006
Externally publishedYes

Fingerprint

Magnesium
Compliance
Potassium
Arteries
Blood Pressure
Healthy Volunteers
Essential Hypertension
Cardiovascular System
Cardiac Output
Vascular Resistance
Antihypertensive Agents
Arterial Pressure
Cardiovascular Diseases
Pharmaceutical Preparations

Keywords

  • Arterial compliance
  • Hypertension
  • Lacidipine
  • Magnesium
  • Potassium

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology

Cite this

Potassium magnesium supplementation for four weeks improves small distal artery compliance and reduces blood pressure in patients with essential hypertension. / Wu, Geru; Tian, Hongyan; Han, Ke; Xi, Yutao; Yao, Yan; Ma, Aiqun.

In: Clinical and Experimental Hypertension, Vol. 28, No. 5, 01.06.2006, p. 489-497.

Research output: Contribution to journalArticle

@article{e2e9e995d18e4d0eb5970ee0e1636e42,
title = "Potassium magnesium supplementation for four weeks improves small distal artery compliance and reduces blood pressure in patients with essential hypertension",
abstract = "It has been postulated that the loss of arterial compliance may precede cardiovascular diseases, and that arterial compliance is an important parameter to consider when evaluating arterial diseases such as essential hypertension (EH) and the effects of antihypertensive treatment. In all, 133 EH patients and 147 healthy subjects were enrolled in this study. Large arterial compliance (C1) and small arterial compliance (C2) were measured by the CVProfilor™ DO-2020 CardioVascular Profiling System. Thirty-five patients randomly received magnesium potassium supplementation (magnesium, 70.8 mg/d; potassium, 217.2 mg/d) for four weeks, and 32 patients received lacidipin (4mg/d) as a control. Before and after the four weeks, blood pressure, C1, and C2 were measured. It was found that arterial compliance was significantly lower in EH patients compared with healthy subjects (C1: 12.53 ± 0.33 vs. 15.63 ± 0.30 ml/mmHg × 10, p + and Mg 2+ supplementation, systolic and diastolic BP decreased 7.83 ± 1.87 mm Hg and 3.67 ± 1.03 mm Hg, and C1 and C2 compliance values increased 12.44{\%} ± 4.43{\%} and 45.25{\%} ± 6.67{\%}, respectively. Decreases in systemic vascular resistance (mean arterial pressure divided by cardiac output) by 11.9{\%} and 16.6 {\%} (p < 0.01) were seen between the drug-induced changes, respectively. Both large arterial compliance and small arterial compliance were decreased in essential hypertension patients. In essential hypertension patients, magnesium and potassium supplementation could improve small arterial compliance, while lacidipine improved large arterial compliance significantly.",
keywords = "Arterial compliance, Hypertension, Lacidipine, Magnesium, Potassium",
author = "Geru Wu and Hongyan Tian and Ke Han and Yutao Xi and Yan Yao and Aiqun Ma",
year = "2006",
month = "6",
day = "1",
doi = "10.1080/10641960600798705",
language = "English (US)",
volume = "28",
pages = "489--497",
journal = "Clinical and Experimental Hypertension",
issn = "1064-1963",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Potassium magnesium supplementation for four weeks improves small distal artery compliance and reduces blood pressure in patients with essential hypertension

AU - Wu, Geru

AU - Tian, Hongyan

AU - Han, Ke

AU - Xi, Yutao

AU - Yao, Yan

AU - Ma, Aiqun

PY - 2006/6/1

Y1 - 2006/6/1

N2 - It has been postulated that the loss of arterial compliance may precede cardiovascular diseases, and that arterial compliance is an important parameter to consider when evaluating arterial diseases such as essential hypertension (EH) and the effects of antihypertensive treatment. In all, 133 EH patients and 147 healthy subjects were enrolled in this study. Large arterial compliance (C1) and small arterial compliance (C2) were measured by the CVProfilor™ DO-2020 CardioVascular Profiling System. Thirty-five patients randomly received magnesium potassium supplementation (magnesium, 70.8 mg/d; potassium, 217.2 mg/d) for four weeks, and 32 patients received lacidipin (4mg/d) as a control. Before and after the four weeks, blood pressure, C1, and C2 were measured. It was found that arterial compliance was significantly lower in EH patients compared with healthy subjects (C1: 12.53 ± 0.33 vs. 15.63 ± 0.30 ml/mmHg × 10, p + and Mg 2+ supplementation, systolic and diastolic BP decreased 7.83 ± 1.87 mm Hg and 3.67 ± 1.03 mm Hg, and C1 and C2 compliance values increased 12.44% ± 4.43% and 45.25% ± 6.67%, respectively. Decreases in systemic vascular resistance (mean arterial pressure divided by cardiac output) by 11.9% and 16.6 % (p < 0.01) were seen between the drug-induced changes, respectively. Both large arterial compliance and small arterial compliance were decreased in essential hypertension patients. In essential hypertension patients, magnesium and potassium supplementation could improve small arterial compliance, while lacidipine improved large arterial compliance significantly.

AB - It has been postulated that the loss of arterial compliance may precede cardiovascular diseases, and that arterial compliance is an important parameter to consider when evaluating arterial diseases such as essential hypertension (EH) and the effects of antihypertensive treatment. In all, 133 EH patients and 147 healthy subjects were enrolled in this study. Large arterial compliance (C1) and small arterial compliance (C2) were measured by the CVProfilor™ DO-2020 CardioVascular Profiling System. Thirty-five patients randomly received magnesium potassium supplementation (magnesium, 70.8 mg/d; potassium, 217.2 mg/d) for four weeks, and 32 patients received lacidipin (4mg/d) as a control. Before and after the four weeks, blood pressure, C1, and C2 were measured. It was found that arterial compliance was significantly lower in EH patients compared with healthy subjects (C1: 12.53 ± 0.33 vs. 15.63 ± 0.30 ml/mmHg × 10, p + and Mg 2+ supplementation, systolic and diastolic BP decreased 7.83 ± 1.87 mm Hg and 3.67 ± 1.03 mm Hg, and C1 and C2 compliance values increased 12.44% ± 4.43% and 45.25% ± 6.67%, respectively. Decreases in systemic vascular resistance (mean arterial pressure divided by cardiac output) by 11.9% and 16.6 % (p < 0.01) were seen between the drug-induced changes, respectively. Both large arterial compliance and small arterial compliance were decreased in essential hypertension patients. In essential hypertension patients, magnesium and potassium supplementation could improve small arterial compliance, while lacidipine improved large arterial compliance significantly.

KW - Arterial compliance

KW - Hypertension

KW - Lacidipine

KW - Magnesium

KW - Potassium

UR - http://www.scopus.com/inward/record.url?scp=33745844830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745844830&partnerID=8YFLogxK

U2 - 10.1080/10641960600798705

DO - 10.1080/10641960600798705

M3 - Article

C2 - 16820345

AN - SCOPUS:33745844830

VL - 28

SP - 489

EP - 497

JO - Clinical and Experimental Hypertension

JF - Clinical and Experimental Hypertension

SN - 1064-1963

IS - 5

ER -